Vaccination in the peripheral stem cell transplant setting for acute myelogenous leukemia: the use of autologous tumor cells with an allogeneic GM-CSF producing cell line

Trial Profile

Vaccination in the peripheral stem cell transplant setting for acute myelogenous leukemia: the use of autologous tumor cells with an allogeneic GM-CSF producing cell line

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2010

At a glance

  • Drugs Tumour cell vaccine-GVAX (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Mar 2010 Results reported in Blood, as reported by BioSante.
    • 22 Dec 2007 Status changed from in progress to completed.
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top